Amgen Inc (AMGN · NASDAQ)
AMGN · MARKET VIEW
Market view · as of Oct 12, 2026
Price (last ~year)
Amgen (AMGN) closed at $414.87, up 1.8% on the day and 9.9% over the past month, trading 14.2% above its 200-day SMA and near the upper end of its 52-week range. The company has beaten earnings estimates in all four of its most recent quarters, including the June quarter's $6.29 versus $5.60 expected, with revenue up 9.5% year over year to $10.05B in the latest quarter and earnings up 64.9%. Quality metrics remain strong — 71.9% gross margin, 35.5% operating margin, and 91.5% ROE — though leverage sits at 3.3x debt/EBITDA on $57.30B of total debt. Recent news flow was mixed, with the stock slipping despite positive obesity trial data on tolerability and retention concerns, while a DCF-based analysis argued shares could be 39% undervalued.
Valuation
- Market cap
- $224.29B
- P/E
- 25.77
- PEG
- 2.451
- P/B
- 18.78
- P/S
- 5.89
- EV/EBITDA
- 14.92
- Beta
- 0.407
- Analyst target
- $395.25
Quality & returns
- Gross margin
- 71.9%
- Operating margin
- 35.5%
- Profit margin
- 23.0%
- ROE
- 91.5%
- ROA
- 8.7%
Price movement
- Last
- $414.87
- 1-month
- +9.9%
- 3-month
- +12.3%
- RSI (14)
- 63
- vs SMA200
- +14.2%
- 52-wk position
- 81.9% -6.6% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $10.05B | $3.51B | $2.38B | $4.55B |
| 2026-03-31 | $8.62B | $2.67B | $1.82B | $3.86B |
| 2025-12-31 | $9.90B | $3.94B | $1.33B | $3.30B |
| 2025-09-30 | $9.56B | $2.53B | $3.22B | $5.91B |
Recent news
- Somewhat-Bearish Why Is Amgen (NASDAQ:AMGN) Sliding Despite Positive Obesity Trial Data? · 2026-10-12
- Somewhat-Bullish Amgen (AMGN) Stock Could Be 39% Undervalued Following KRAS Market Growth · 2026-10-11
- Somewhat-Bullish Moderna Stock Surge Puts These Oncology Biotechs On Retail Investors Radar · 2026-10-11
- Neutral Certain Options of Silence Therapeutics plc are subject to a Lock-Up Agreement Ending on 11-OCT-2026. · 2026-10-11
- Somewhat-Bullish Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative · 2026-10-10
- Somewhat-Bullish Amgen stock trades at USD 414.87 versus USD 407.44 in U.S. trading · 2026-10-10
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)